← Leaderboards
Yan Cui
Louisiana State Univ Hsc New Orleans
$6,316,976
Attributed
$6,316,976
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $686.1K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,316,976 · 8
By mechanism
R01$5,217,290 · 3
P20$678,749 · 4
R21$420,937 · 1
Top collaborators
No co-investigators on record.
Most similar at Louisiana State Univ Hsc New Orleans
Same institution · by research overlap
- Paul L Fidel$10,381,300
- Augusto C Ochoa$52,418,882
- Michael Edward Hagensee$4,706,892
- Jill Gilbert$734,194
- Jack P Strong$1,804,288
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneTumorMalignant NeoplasmsNeoplasm MetastasisT-LymphocyteTumor MicroenvironmentCellsInsightT-Cell ActivationLymphoidFibroblastsProgenitorCytokinePathway InteractionsDendritic CellsMyelogenousLinkMediatingTumor ProgressionMutationToxic EffectImmunotherapyMolecularBase
Grant awards (21)
Targeting the CD73-adenosinergic pathway in head and neck cancer$677,163
R01 · FY2025 · DE · contact PI
Targeting the CD73-adenosinergic pathway in head and neck cancer$668,298
R01 · FY2024 · DE · contact PI
Targeting the CD73-adenosinergic pathway in head and neck cancer$686,127
R01 · FY2023 · DE · contact PI
CD73 expression on cancer-associated fibroblasts of Head and Neck Cancers shapes the immune landscape$192,187
R21 · FY2020 · DE · contact PI
CD73 expression on cancer-associated fibroblasts of Head and Neck Cancers shapes the immune landscape$228,750
R21 · FY2019 · DE · contact PI
P53 inactivation on MDSC development and tumor progression$315,400
R01 · FY2017 · CA · contact PI
P53 inactivation on MDSC development and tumor progression$315,400
R01 · FY2016 · CA · contact PI
P53 inactivation on MDSC development and tumor progression$315,054
R01 · FY2015 · CA · contact PI
P53 inactivation on MDSC development and tumor progression$303,590
R01 · FY2014 · CA · contact PI
P53 inactivation on MDSC development and tumor progression$298,800
R01 · FY2013 · CA · contact PI
In vivo targeted DC vaccine to activate anti-tumor CTL$338,640
R01 · FY2009 · CA · contact PI
In vivo targeted DC vaccine to activate anti-tumor CTL$270,382
R01 · FY2009 · CA · contact PI
In vivo targeted DC vaccine to activate anti-tumor CTL$329,612
R01 · FY2008 · CA · contact PI
OVERCOMING TUMOR TOLERANCE THROUGH IN VIVO GENERATED DENDRITIC CELLS$138,042
P20 · FY2008 · RR · contact PI
LSUHSC COBRE:PROJ 2: OVERCOMING TUMOR TOLER THROUGH IN VIVO GEN* DENDRITIC CELLS$141,811
P20 · FY2007 · RR · contact PI
In vivo targeted DC vaccine to activate anti-tumor CTL$108,340
R01 · FY2007 · CA · contact PI
In vivo targeted DC vaccine to activate anti-tumor CTL$248,209
R01 · FY2006 · CA · contact PI
LSUHSC COBRE:PROJ 2: OVERCOMING TUMOR TOLER THROUGH IN VIVO GEN* DENDRITIC CELLS$197,595
P20 · FY2006 · RR · contact PI
In vivo targeted DC vaccine to activate anti-tumor CTL$88,092
R01 · FY2006 · CA · contact PI
In vivo targeted DC vaccine to activate anti-tumor CTL$254,183
R01 · FY2005 · CA
LSUHSC COBRE:PROJ 2: OVERCOMING TUMOR TOLERANCE$201,301
P20 · FY2005 · RR